Centene Corporation

NYSE:CNC Aktierapport

Börsvärde: US$28.5b

Centene Framtida tillväxt

Future kriterier kontrolleras 3/6

Centene förväntas öka intäkter och intäkter med 66.9% respektive 3.6% per år. EPS förväntas tillväxt med 65.2% per år. Avkastningen på eget kapital förväntas bli 9.5% om 3 år.

Viktig information

66.9%

Tillväxttakt i vinsten

65.24%

Tillväxttakt för EPS

Healthcare vinsttillväxt18.3%
Intäkternas tillväxttakt3.6%
Framtida avkastning på eget kapital9.53%
Bevakning av analytiker

Good

Senast uppdaterad22 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • May 16

CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty

Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.
Uppdatering av berättelse • Apr 29

CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside

Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.
Seeking Alpha • Apr 28

Centene: Big Comeback Story

Summary Centene Corporation delivered a strong Q1 earnings beat, signaling a robust turnaround after a challenging year for health insurers. Q1 revenue surged to $49.94 billion, up 7.1% year-over-year and $2.4 billion above consensus, driven by premium yield and Medicaid growth. Cost discipline was evident as the health benefits ratio fell to 87.3% and SG&A expenses declined, fueling a $1.24 adjusted EPS beat versus consensus. CNC raised 2026 revenue and EPS guidance, now projecting at least $3.40 adjusted EPS—a 63.4% year-over-year increase—supporting a bullish re-rating and buy recommendation. Read the full article on Seeking Alpha
Uppdatering av berättelse • Apr 15

CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power

Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.
Uppdatering av berättelse • Apr 01

CNC: Government Program Margins In 2026 Will Support Future Earnings Power

Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.
Uppdatering av berättelse • Mar 18

CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power

Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.
Uppdatering av berättelse • Mar 04

CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance

Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.
Uppdatering av berättelse • Feb 17

CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook

Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.
Uppdatering av berättelse • Feb 03

CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery

Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.
Uppdatering av berättelse • Jan 20

CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power

Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.
Uppdatering av berättelse • Jan 06

CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook

Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.
Uppdatering av berättelse • Dec 19

CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead

Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.
Uppdatering av berättelse • Dec 05

CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds

Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.
Uppdatering av berättelse • Nov 21

CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside

Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.
Uppdatering av berättelse • Nov 06

CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects

Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.
Uppdatering av berättelse • Oct 22

Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds

Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.
Uppdatering av berättelse • Oct 08

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.
Uppdatering av berättelse • Sep 19

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.
Analysartikel • Sep 12

Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
Uppdatering av berättelse • Sep 04

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.
Analysartikel • Jul 03

Why Investors Shouldn't Be Surprised By Centene Corporation's (NYSE:CNC) 38% Share Price Plunge

Unfortunately for some shareholders, the Centene Corporation ( NYSE:CNC ) share price has dived 38% in the last thirty...
Seeking Alpha • Mar 26

Centene: A Leader In Government-Sponsored Insurance And Its Prospects

Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking Alpha
Seeking Alpha • Mar 18

Centene Corporation Is Resilient And Will Thrive

Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Centene: Attractive Risk-Reward For A Growing Company At A Value Price

Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking Alpha
Seeking Alpha • Oct 22

Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024

Summary Centene, a leading health insurer, shows strong fundamentals and growth despite sector challenges, making it a "Buy" at a target price of $70/share. The company’s 2Q24 results indicate robust earnings growth and increasing membership, contrasting with peers like Humana, which face significant declines. Centene's valuation at $61/share with a P/E of 9x is attractive, projecting a potential 27.17% annualized upside until 2026. Despite lacking a dividend, Centene's stability and growth prospects in government programs and managed healthcare segments justify a conservative investment approach. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NYSE:CNC - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/2028197,9022,4862,5463,93511
12/31/2027190,8591,6361,6072,72014
12/31/2026190,3751,2222,7474,16414
3/31/2026178,332-6,4447,1127,944N/A
12/31/2025176,151-6,6744,3215,088N/A
9/30/2025167,285-5,2903,3564,064N/A
6/30/2025159,2682,0541,0801,730N/A
3/31/2025153,2443,4531,4922,120N/A
12/31/2024147,1453,305-490154N/A
9/30/2024146,3523,067245958N/A
6/30/2024144,2022,8232,2612,957N/A
3/31/2024142,9492,7352,6033,328N/A
12/31/2023141,3932,7027,2548,053N/A
9/30/2023139,3642,4445,4516,260N/A
6/30/2023138,1112,7137,6518,571N/A
3/31/2023136,9411,4838,3929,379N/A
12/31/2022135,9991,2025,2576,261N/A
9/30/2022132,7562,0147,4938,512N/A
6/30/2022129,2281,8605,9856,982N/A
3/31/2022124,1811,4974,3485,313N/A
12/31/2021118,5731,3473,2954,205N/A
9/30/2021114,1307365,6436,511N/A
6/30/2021111,2847202,8633,757N/A
3/31/2021108,1582,4614,9075,786N/A
12/31/2020104,2801,8084,6345,503N/A
9/30/202095,7642,0291,0081,871N/A
6/30/202086,5231,5561,9182,724N/A
3/31/202078,105845-804-73N/A
12/31/201970,8071,321N/A1,483N/A
9/30/201968,3851,353N/A1,500N/A
6/30/201965,5071,277N/A2,147N/A
3/31/201961,0281,082N/A704N/A
12/31/201856,688900N/A1,234N/A
9/30/201852,618889N/A2,318N/A
6/30/201848,6551,075N/A1,867N/A
3/31/201847,2011,029N/A2,087N/A
12/31/201745,810828N/A1,489N/A
9/30/201744,870853N/A2,631N/A
6/30/201743,646796N/A3,016N/A
3/31/201742,468713N/A2,903N/A
12/31/201637,693562N/A1,851N/A
9/30/201632,839416N/A460N/A
6/30/201628,062360N/A40N/A
3/31/201622,948277N/A809N/A
12/31/201521,292356N/A658N/A
9/30/201519,854350N/A827N/A
6/30/201518,548339N/A1,206N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: CNC förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.5% ).

Resultat vs marknad: CNC förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: CNC förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: CNC s intäkter ( 3.6% per år) förväntas växa långsammare än marknaden för US ( 11.7% per år).

Hög tillväxtintäkter: CNC s intäkter ( 3.6% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: CNC s avkastning på eget kapital förväntas bli låg om 3 år ( 9.5 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/22 00:02
Aktiekurs vid dagens slut2026/05/22 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Centene Corporation bevakas av 34 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays